- Conditions
- Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
- Interventions
- Tagraxofusp, Azacitidine (AZA), Venetoclax
- Drug
- Lead sponsor
- Jacqueline Garcia, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 9,283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 33
- States / cities
- Long Beach, California • Los Angeles, California • Oakland, California + 21 more
- Conditions
- Hepatic Impairment
- Interventions
- Telotristat Ethyl
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Advanced Cancer
- Interventions
- LY2875358, LY2875358 + erlotinib, LY2875358 at Part A highest dose, LY2875358 at Part A highest dose + trametinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Glioma
- Interventions
- M032
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 36 Months and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Pancreatitis
- Interventions
- NI-03, Placebo
- Drug
- Lead sponsor
- Kangen Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Stanford, California + 24 more
- Conditions
- Healthy
- Interventions
- PF-06427878, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Sleep Disturbances, Depression
- Interventions
- High Active intervention, Inactive intervention, Mid Level Active Intervention
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Albany, New York • New York, New York
- Conditions
- Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
- Interventions
- MEDI3617, Bevacizumab, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Stanford, California • Lafayette, Indiana + 7 more
- Conditions
- Solid Tumor
- Interventions
- 14C-labeled poziotinib
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Migraine
- Interventions
- PF-05180999, Placebo, 120 mg MR PF-05180999, 360 mg MR PF-05180999, 10 mg cetirizine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- HIV Infections
- Interventions
- VSV-Indiana HIV gag vaccine, Placebo injection (normal saline)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2011
- U.S. locations
- 4
- States / cities
- San Francisco, California • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more
- Conditions
- Lymphoma
- Interventions
- ofatumumab
- Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 48
- States / cities
- Lewes, Delaware • Newark, Delaware • Weston, Florida + 34 more
- Conditions
- Advanced Solid Tumors, Malignant Neoplasm
- Interventions
- MK-3120
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Miami, Florida • Hackensack, New Jersey + 4 more
- Conditions
- Healthy Volunteers, Chronic Kidney Disease
- Interventions
- IGT-303, Placebo
- Drug
- Lead sponsor
- Ingenia Therapeutics INC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Lakeland, Florida • Statesville, North Carolina + 1 more
- Conditions
- Solid Tumors
- Interventions
- JAB-30355
- Drug
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Lake Mary, Florida • St Louis, Missouri + 4 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- JZP341
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Sarasota, Florida • Baltimore, Maryland + 5 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Treatment with ARQ 197 in combination with gemcitabine
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
- Conditions
- Advanced Solid Tumor
- Interventions
- M9466, Irinotecan, Folinic acid, Fluorouracil (5-FU), Bevacizumab, Granulocyte colony stimulating factor (G-CSF)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Pennington, New Jersey • Nashville, Tennessee + 1 more
- Conditions
- Neoplasms, Prostate
- Interventions
- GSK5471713
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- La Jolla, California • Los Angeles, California • Grand Rapids, Michigan + 2 more
- Conditions
- SARS-CoV-2, Influenza
- Interventions
- Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 1,758 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 69
- States / cities
- Chandler, Arizona • Colton, California • Huntington Beach, California + 59 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ABI-011
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • San Antonio, Texas
- Conditions
- Lymphoma
- Interventions
- apolizumab
- Biological
- Lead sponsor
- PDL BioPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Freemont, California
- Conditions
- Bladder Cancer, Urinary Bladder Neoplasms
- Interventions
- MK-3120
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Bakersfield, California • New Brunswick, New Jersey • Myrtle Beach, South Carolina + 1 more